Natco Pharma Limited {NSE: NATCOPHARM; BSE: 524816) is pleased to announce the launch of Rivaroxaban molecule, under brand RPIGAT.

Rivaroxaban is an anticoagulant medication used to treat and prevent blood clots.

Rivaroxaban is currently sold by Bayer under brand name of Xarelto, in the lndianmarket.

After successful previous launches of DABIGAT (Dabigatran) and AP IGAT (Apixaban) by NATCO, this latest Rivaroxaban NOAC (Novel oral anti-coagulant) is in line with our Company's mission of affordable medicines accessible to all. NATCO has launched RPIGAT in four strengths- 20 mg, 15 mg, 10 mg and 2.5 mg. The 20 mg strength is priced at an MRP of INR 14.0 per tablet.

Contact:

Tel: +91-40-2354 7532

Web: www.natcopharma.com

(C) 2020 Electronic News Publishing, source ENP Newswire